Total Funding
70
62
Total FundingPrivate Equity raised
Growth Score
-10 pts
Heat Score
-12 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
43929
Sotio is a biotechnology company developing a new immunotherapy based on activated dendritic cells for the treatment of cancer.
- Vivi Boura: Chief Medical OfficerPast Role: Sotio, Deputy Chief Medical Officer
- Robyn Hunter: Chief Financial Officer
About the Company
Sotio is an international biotechnology company leading the efforts of PPF Group to build a diverse biotechnology portfolio through its own research & development, collaborations, in-licensing, investments, mergers, and acquisitions. The company is developing new medical therapies, focusing on the treatment of cancer and autoimmune diseases.
The most advanced project is the SOTIO proprietary platform of active cellular immunotherapy (ACI) based on dendritic cells.
